Skip to main content

Table 1 Main parameters of the disease and disability resulting from myoclonus; pharmacological treatment

From: The network sustaining action myoclonus: a MEG-EMG study in patients with EPM1

Patient N, gender

Age (years)

Disease Onset (years)

Disease Duration (years)

Score

Treatment (daily dose in mg)

#1, F

28

11

17

2

VPA 1200, LEV 1000, TPM 200

#2, M

27

16

11

1

VPA 1750, LEV 3000

#3, M

43

14

29

1

VPA 1500, ZNS 200

#4, M

52

17

35

1

VPA 2400, PB 50

#5, F

23

11

12

2

VPA 1150, LEV 1750

#6, M

54

15

39

2

VPA 2500, ZNS 200

#7, M

50

16

34

4

VPA 1800, CZP 1, TPM 300, ZNS 500

#8, M

60

16

44

3

VPA 1200, PB 150, CZP 1

#9, F

70

14

56

5

VPA 1300, LEV 2000, TPM 100, CZP 4

#10, F

26

11

15

3

VPA 1750, ZNS 300

  1. Legend: Score: assessed according to a simplified functional scale [17]: treatment: VPA valproate, TPM topiramate, LEV levetiracetam, ZNS zonisamide, PB phenobarbital, CZP clonazepam